Recent blog posts
Drug Highlight
15 min read
Global New Drug Research and Development Progress Weekly Report(6.3-6.9)
11 June 2024
6.3-6.9 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
16 min read
Global New Drug Research and Development Progress Weekly Report(5.27-6.2)
3 June 2024
5.27-6.2 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
18 min read
Global New Drug Research and Development Progress Weekly Report(5.13-5.19)
20 May 2024
5.13-5.19 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
15 min read
Global New Drug Research and Development Progress Weekly Report(5.6-5.12)
14 May 2024
5.6-5.12 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
9 min read
Global New Drug Research and Development Progress Weekly Report(4.29-5.5)
7 May 2024
4.29-5.5 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
7 min read
Global first IL-15 drug approved! ImmunityBio's Anktiva receives FDA approval for the treatment of Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer
23 April 2024
On April 22, 2024, ImmunityBio's Anktiva (N-803) plus BCG got FDA approval for BCG-unresponsive NMIBC with CIS, with/without papillary tumors.
Drug Highlight
14 min read
Global New Drug Research and Development Progress Weekly Report(4.15-4.21)
22 April 2024
4.15-4.21 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
18 min read
Global New Drug Research and Development Progress Weekly Report(4.8-4.14)
15 April 2024
4.8-4.14 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Drug Highlight
5 min read
Summary of Global Clinical Trial Failures in March 2024
12 April 2024
The article presents the clinical trial outcomes that failed globally in March.
Drug Highlight
9 min read
Summary of Global Clinical Trial Failures in February 2024
12 April 2024
The article presents the clinical trial outcomes that failed globally in February.
Drug Highlight
9 min read
2024 AACR Conference: Clinical Progress of ADC Therapeutics
11 April 2024
Up to now, at the AACR meeting, updates on the clinical progress of several ADC drugs have been presented, involving targets such as HER2, BCMA, CD123, FRα, CCR7, Axl, etc.
Drug Highlight
6 min read
Summary of Global Clinical Trial Failures in January 2024
11 April 2024
The failure of clinical trials can stem from multiple factors. One study suggests that 90% of drug development clinical failures may be attributed to four reasons: lack of clinical efficacy (40%-50%), uncontrollable toxicity (30%), poor pharmacokinetic properties (10%-15%), and absence of commercial demand or poor strategic planning (10%).